Inhibition of Daptomycin by Pulmonary Surfactant: In Vitro Modeling and Clinical Impact
The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Abstract
The lipopeptide daptomycin has been approved for use in skin and skin-structure infections but has failed to meet statistical noninferiority criteria in a clinical trial for severe community-acquired pneumonia. Daptomycin exhibited an unusual pattern of activity in pulmonary animal models: efficacy in Staphylococcus aureus hematogenous pneumonia and inhalation anthrax but no activity against Streptococcus pneumoniae in simple bronchial-alveolar pneumonia. Daptomycin was shown to interact in vitro with pulmonary surfactant, resulting in inhibition of antibacterial activity. This effect was specific to daptomycin and consistent with its known mechanism of action. This represents the first example of organ-specific inhibition of an antibiotic.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Daptomycin is inhibited by pulmonary surfactant 160 and thus is contraindicated in the treatment of S aureus pneumonia acquired via the aspiration route.”
Citations
Cites
Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically
Ferraro, M. J. (2000) · Medical Entomology and Zoology · Cited by 17,248
Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically
Ferraro, M. J. (2000) · Cited by 16,875
Pulmonary surfactant: functions and molecular composition
Goerke, J. (1998) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/s0925-4439(98)00060-x · Cited by 724 · cited 3×
“pulmonary surfactant is different from that of most eukaryotic membranes; it primarily contains PC and only low levels of cholesterol and sphingolipids [3].”
BackgroundInfluentialCorrelation of Daptomycin Bactericidal Activity and Membrane Depolarization in Staphylococcus aureus
Silverman, J. A., Perlmutter, N. G., & Shapiro, H. M. (2003) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.47.8.2538-2544.2003 · Cited by 656 · cited 2×
“molecular synthesis, and cell death [7].”
BackgroundSelf-citationIn Vivo Pharmacodynamic Activity of Daptomycin
Safdar, N., Andes, D., & Craig, W. A. (2004) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.48.1.63-68.2004 · Cited by 370 · cited 1×
“pneumoniae, including skin and soft tissue (thigh) infections [10], meningitis [11], and endocarditis [12], but has specifically failed in a simple model of BAP (table 1).”
BackgroundCarpenter, C. F., & Chambers, H. F. (2004) · Clinical Infectious Diseases · doi:10.1086/383472 · Cited by 358 · cited 1×
“class of antibiotics, the lipopeptides [6].”
Structural Transitions as Determinants of the Action of the Calcium-Dependent Antibiotic Daptomycin
Jung, D., Rozek, A., Okon, M., & Hancock, R. E. W. (2004) · Chemistry & Biology · doi:10.1016/j.chembiol.2004.04.020 · Cited by 297 · cited 3×
“Daptomycin is inserted into the membrane of gram-positive bacteria and artificial lipid vesicles [7, 15, 16].”
BackgroundPenetration of Antibiotics into Respiratory Secretions
Pennington, J. E. (1981) · Clinical Infectious Diseases · doi:10.1093/clinids/3.1.67 · Cited by 192
Extraction, Characterization, and Cellular Localization of the Lipids of Staphylococcus aureus
White, D. C., & Frerman, F. E. (1967) · Journal of Bacteriology · doi:10.1128/jb.94.6.1854-1867.1967 · Cited by 184 · cited 1×
“Surfactant is also ∼10% PG, a prominent component of the gram-positive plasma membrane [18].”
BackgroundSakoulas, G., Eliopoulos, G. M., Alder, J. D., & Eliopoulos, C. T. (2003) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.47.5.1714-1718.2003 · Cited by 133 · cited 1×
“pneumoniae, including skin and soft tissue (thigh) infections [10], meningitis [11], and endocarditis [12], but has specifically failed in a simple model of BAP (table 1).”
BackgroundSelf-citation
Cited by
Items 301–400 of 548
The Use of Daptomycin for Staphylococcus Aureus Infections in Critical Care Medicine
Alder, J. D. (2008) · Critical Care Clinics · doi:10.1016/j.ccc.2007.12.010 · Cited by 16
Self-citationKwong, J. C., Chua, K., & Charles, P. G. P. (2012) · Current Infectious Disease Reports · doi:10.1007/s11908-012-0254-8 · Cited by 13
Surgical Infections and Antibiotic Use
Barie, P. S. (2012) · Elsevier eBooks · doi:10.1016/b978-1-4377-1560-6.00012-3 · Cited by 15
Sulaiman, H., Abdul-Aziz, M. H., & Roberts, J. A. (2017) · Seminars in Respiratory and Critical Care Medicine · doi:10.1055/s-0037-1602716 · Cited by 13
Nussbaumer-Pröll, A. K., & Zeitlinger, M. A. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12080773 · Cited by 13
Napolitano, L. M. (2005) · Surgical Infections · doi:10.1089/sur.2005.6.s2-5 · Cited by 15
“Daptomycin does not achieve adequate intrapulmonary tissue concentrations, and there is evidence that the drug is inactivated by pulmonary surfactant [42a].”
Gold, H. S., & Pillai, S. K. (2009) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2008.10.008 · Cited by 17
Empirical antimicrobial treatment in haemato-/oncological patients with neutropenic sepsis
Vossen, M. G., Milacek, C., & Thalhammer, F. (2018) · ESMO Open · doi:10.1136/esmoopen-2018-000348 · Cited by 14
“Daptomycin has a low significance in patients with neutropenic fever as most suffer from respiratory tract infections, and daptomycin shows no activity in pulmonary tissue due to inhibition by pulmonary surfactant.(28) High-risk patients with prior ICU admission and/or prolonged steroid exposure showing signs of parti…”
BackgroundDaptomycin and tigecycline: a review of clinical efficacy in the antimicrobial era
Ziglam, H. M. (2007) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.8.14.2279 · Cited by 14
“These findings may be due to significant reduction in activity of daptomycin in the presence of pulmonary surfactant [48] .”
BackgroundAstigarraga, P. M. O., Garnacho‐Montero, J., Grau, S., Colomo, Ó. R., Palomar, M., Zaragoza, R., García-Paredes, P. M., Cerdá, E., & Lerma, F. Á. (2007) · Medicina Intensiva · doi:10.1016/s0210-5691(07)74829-5 · Cited by 12
Koeth, L. M., DiFranco-Fisher, J. M., Scangarella-Oman, N. E., & Miller, L. A. (2017) · Journal of Clinical Microbiology · doi:10.1128/jcm.02366-16 · Cited by 12
“fSurfactant (Survanta; Abbott Pharmaceuticals) was added to CAMHB to achieve the stated surfactant concentrations (19).”
BackgroundMethodReilly, J., Jacobs, M. A., Friedman, B. C., Cleveland, K. O., Lombardi, D. A., & Castañeda-Ruiz, B. (2020) · Drugs - Real World Outcomes · doi:10.1007/s40801-020-00191-x · Cited by 12
“Moreover, daptomycin is inactivated by pulmonary surfactants and is unsuitable for bacteremic patients with a respiratory focus of infection [11].”
BackgroundDiagnosis and management of community-associated MRSA infections in children
Long, C. B., Madan, R. P., & Herold, B. C. (2010) · Expert Review of Anti-infective Therapy · doi:10.1586/eri.09.127 · Cited by 12
Gram-Positive Cocci Infections in Intensive Care: Guide to Antibacterial Selection
Álvarez-Lerma, F., Grau, S., & Gracia-Arnillas, M. P. (2006) · Drugs · doi:10.2165/00003495-200666060-00003 · Cited by 13
Levison, M. E., & Fung, S. M. (2006) · Current Infectious Disease Reports · doi:10.1007/s11908-006-0031-7 · Cited by 12
“Although daptomycin was effective in an animal model of experimental S. aureus hematogenous pneumonia, this drug was ineffective in experimental Streptococcus pneumoniae bronchial-alveolar pneumonia and was found not to be effective in a clinical trial for the treatment of severe community-acquired pneumonia, perhaps…”
BackgroundStructure–Interaction Relationship of Polymyxins with Lung Surfactant
Jiang, X., Patil, N. A., Xu, Y., Wickremasinghe, H., Zhou, Q. T., Zhou, F., Thompson, P. E., Wang, L., Xiao, M., Roberts, K. D., et al. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c01497 · Cited by 12
Martín-Galiano, A. J., Yuste, J., Cercenado, M. I., & de la Campa, A. G. (2014) · BMC Genomics · doi:10.1186/1471-2164-15-652 · Cited by 11
“Moreover, these new drugs are associated with undesirable side effects [3,4] and may suffer inactivation in some parts of the body [5].”
A Review of Pyridine and Pyrimidine Derivatives as Anti-MRSA Agents
Kumar, P., Kumar, A., Singh, A. K., & Thareja, S. (2022) · Anti-Infective Agents · doi:10.2174/2211352520666220705085733 · Cited by 12
In vitro activity of telavancin and comparators against selected groups of Gram-positive cocci
Hope, R., Chaudhry, A., Adkin, R., & Livermore, D. M. (2013) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2012.10.016 · Cited by 11
“Since dapomycin is irrelevant to pulmonary infection, being inactivated by ung surfactant [9], it was replaced by penicillin against S.”
BackgroundDean, N. C. (2010) · Hospital Practice · doi:10.3810/hp.2010.02.274 · Cited by 12
“Because daptomycin is inactivated by pulmonary surfactant, it is not recommended for use in the treatment of pneumonia.(32)”
BackgroundDaptomycin approved in Japan for the treatment of methicillin-resistant Staphylococcus aureus
Hagihara, M., Umemura, Mori, & Mikamo (2012) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s23875 · Cited by 12
“39 Daptomycin is inactivated by surfactant in the lung and is not indicated for the treatment of pneumonia, 40,41 and is not to be used to treat pneumonia and left-sided endocarditis.”
Outcomes analysis of daptomycin use in a community hospital
Fossaceca, C. (2007) · Advances in Therapy · doi:10.1007/bf02848774 · Cited by 11
ENTEROCOCCAL AND VIRIDANS STREPTOCOCCAL INFECTIONS
English, B. K., & Shenep, J. L. (2009) · Elsevier eBooks · doi:10.1016/b978-1-4160-4044-6.50100-x · Cited by 12
Antibiotic therapeutic options for infections caused by drug-resistant Gram-positive cocci
Banwan, K., Senok, A. C., & Rotimi, V. O. (2009) · Journal of Infection and Public Health · doi:10.1016/j.jiph.2009.04.003 · Cited by 10
The pure erythroleukemia: a case report and literature review.
Latif, N., Salazar, E., Khan, R., Villas, B., & Rana, F. N. (2010) · PubMed · Cited by 10
Ghazi, I. M., Grupper, M., & Nicolau, D. P. (2017) · Annals of Clinical Microbiology and Antimicrobials · doi:10.1186/s12941-017-0178-0 · Cited by 10
Unexpected Outcome of Daptomycin-induced Eosinophilic Pneumonia: Rarity Within a Rarity
Raza, A., Arslan, A., Atiq, M. U., Chan, V., & Patel, R. K. (2019) · Cureus · doi:10.7759/cureus.6271 · Cited by 10
“Additionally, eotaxin (a potent eosinophil chemoattractant) production by alveolar macrophages, pulmonary endothelial cells, airway smooth muscle cells, and alveolar epithelial cells leads to further accumulation of eosinophils in the lungs [3].”
BackgroundZainah, H., Zervos, M., Stephane, W., Alhelo, S. C., Alkhoury, G., & Weinmann, A. J. (2013) · Case Reports in Infectious Diseases · doi:10.1155/2013/653582 · Cited by 10
“It is known to be inactivated by alveolar surfactant, which eliminates its use in pneumonia; that has been shown in vitro as the first organ-specific inhibition of an antibiotic [10].”
An efficient chemical synthesis of carboxylate-isostere analogs of daptomycin
Yoganathan, S., Yin, N., He, Y. Q., Mesleh, M. F., Gu, Y. G., & Miller, S. J. (2013) · Organic & Biomolecular Chemistry · doi:10.1039/c3ob40924d · Cited by 10
Lother, S., & Press, N. (2017) · Current Infectious Disease Reports · doi:10.1007/s11908-017-0599-0 · Cited by 9
Mehta, Y. B., Sutar, A. R., Zirpe, K. G., Kothari, J., Alapati, C., Pathak, M., Nagvekar, V. C., Mehta, K. D., & Debnath, K. (2022) · International Journal of Applied and Basic Medical Research · doi:10.4103/ijabmr.ijabmr_602_21 · Cited by 9
“[5] Daptomycin, though bactericidal, is inactivated in the lungs, therefore, it is not approved for the treatment of pneumonia.[6] Moreover, all the above mentioned MRSA antibiotics do not provide coverage of common Gram-negative pathogens necessitating the use of add-on therapies for managing polymicrobial infections…”
BackgroundTalbot, G. H. (2010) · Clinical Infectious Diseases · doi:10.1086/653064 · Cited by 9
Oberholzer, C. M., & Caserta, M. T. (2005) · The Pediatric Infectious Disease Journal · doi:10.1097/01.inf.0000181741.59226.a0 · Cited by 9
Pathogens Resistant to Antibacterial Agents
Chen, L. F., Chopra, T., & Kaye, K. S. (2011) · Medical Clinics of North America · doi:10.1016/j.mcna.2011.03.005 · Cited by 17
[New therapeutic options for the treatment of multiresistant bacteria in the ICU].
Gaite, F. B., Jover-Sáenz, A., Vidal, M. V., & Perelló, D. C. (2008) · PubMed · Cited by 9
Optimizing Therapy for MRSA Pneumonia
Skrupky, L. P., Micek, S. T., & Kollef, M. H. (2007) · Seminars in Respiratory and Critical Care Medicine · doi:10.1055/s-2007-996408 · Cited by 9
“Daptomycin Daptomycin should not be used in the treatment of MRSA pneumonia because the drug’s activity is inhibited by pulmonary surfactant.(67) OPTIMIZING THERAPY FOR MRSA PNEUMONIA/SKRUPKY ET AL 619”
BackgroundZhao, X., Blotske, K., Cargile, M., Tilley, A., Murray, B., Gao, Y., Henry, K., Smith, S. E., Barreto, E. F., Bauer, S. R., et al. (2025) · medRxiv · doi:10.64898/2025.12.01.25341004 · Cited by 12
Establishing the reference broth microdilution MIC method for cefepime-taniborbactam
Belley, A. C., Cusick, S. M., Pevear, D. C., Koeth, L. M., DiFranco-Fisher, J. M., Kothari, N., Hawser, S., & Moeck, G. (2025) · Journal of Clinical Microbiology · doi:10.1128/jcm.00661-25 · Cited by 8
Machhua, P., Unnithan, V. G., Liu, Y., Jiang, Y., Zhang, L., & Guo, Z. (2024) · eLife · doi:10.7554/elife.93267.3 · Cited by 8
Current and emerging pharmacotherapy for the treatment of infections following open-heart surgery
Giacobbe, D. R., Corcione, S., Salsano, A., Puente, F. D., Pinna, S. M., Rosa, F. G. D., Mikulska, M., Santini, F., & Viscoli, C. (2019) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2019.1574753 · Cited by 9
“On the other hand, it should not be used for VAP, as its activity is significantly impaired by the presence of surfactant [148].”
BackgroundEkkelenkamp, M. B., Rooijakkers, S. H. M., & Bonten, M. J. M. (2010) · Elsevier eBooks · doi:10.1016/b978-0-323-04579-7.00165-9 · Cited by 8
MRSA Septicemia With Septic Arthritis and Prostatic, Intraretinal, Periapical, and Lung Abscesses.
Denu, R. A., Patel, D., Becker, B. J., Shiffler, T., & Kleinschmidt, P. C. (2020) · PubMed · Cited by 8
Pathogenesis of Staphylococcus aureus in Humans
Lu, T., & DeLeo, F. R. (2015) · Wiley eBooks · doi:10.1002/9781118644843.ch39 · Cited by 11
Paul, S., Ishida, H., Nguyen, L. T., Liu, Z., & Vogel, H. J. (2017) · Protein Science · doi:10.1002/pro.3138 · Cited by 10
“trials daptomycin failed to treat community-acquired pneumonia patients due to sequestration of daptomycin by pulmonary surfactant.(5) Alteration of cell membrane and cell wall components by various mechanisms has also been proposed for the emerging resistance toward daptomycin.”
BackgroundRaru, Y., Zeid, F. M., Browning, S., & Saunders, E. (2017) · Respiratory Medicine Case Reports · doi:10.1016/j.rmcr.2017.11.003 · Cited by 8
“FDA's review identified 7 definite, 13 probable and 38 possible cases of eosinophilic pneumonia between 2004 and 2010 that were most likely associated with Daptomycin as [3,4] (see Table 1).”
BackgroundInfluentialManagement of cSSTIs:the role of daptomycin
Garau, J. (2006) · Current Medical Research and Opinion · doi:10.1185/030079906x148292 · Cited by 8
Prytherch, Z. C., & BéruBé, K. (2014) · Alternatives to Laboratory Animals · doi:10.1177/026119291404200607 · Cited by 7
Nussbaumer-Pröll, A. K., Eberl, S., Belley, A. C., Knechtle, P., Huband, M. D., Huynh, H. K., & Zeitlinger, M. A. (2023) · The Journal of Antibiotics · doi:10.1038/s41429-022-00592-w · Cited by 7
“One of the most prominent examples of reduced activity in vivo has been shown for daptomycin [1].”
BackgroundIn Vitro Mechanistic Study of the Distribution of Lascufloxacin into Epithelial Lining Fluid
Ohya, K., Takano, J., & Manita, S. (2019) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02208-18 · Cited by 7
“pulmonary surfactant, resulting in inactivation of antibacterial activity (22).”
BackgroundEosinophilic pneumonia: a case of daptomycin induced lung injury
Raman, V., Chaudhary, I., & Shieh, S. (2021) · Journal of Community Hospital Internal Medicine Perspectives · doi:10.1080/20009666.2021.1883813 · Cited by 7
“This injury will then activate alveolar macrophages and initiate the process of eosinophil accumulation [12].”
BackgroundBaltz, R. H. (2014) · Wiley eBooks · doi:10.1002/9781118794623.ch23 · Cited by 7
Talbot, G. H. (2008) · Clinical Infectious Diseases · doi:10.1086/591401 · Cited by 7
Potency of Meropenem-Vaborbactam in Lung Surfactant
Rubio-Aparicio, D., Loutit, J. S., Dudley, M. N., & Lomovskaya, O. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01702-17 · Cited by 7
“Daptomycin efficacy in clinical trials for community-associated pneumonia (CAP) was unexpectedly low, and it was subsequently demonstrated that pulmonary surfactant reduced its antibacterial activity, providing a mechanistic explanation for its clinical failure (1).”
BackgroundInfluentialAstigarraga, P. M. O., Garnacho‐Montero, J., Grau, S., Colomo, Ó. R., Palomar, M., Zaragoza, R., García-Paredes, P. M., Cerdá, E., & Lerma, F. Á. (2007) · Enfermedades Infecciosas y Microbiología Clínica · doi:10.1157/13108709 · Cited by 9
Monogue, M. L., Sanders, J. M., Mercuro, N. J., Hodge, C. K., Golnabi, E. Y., Carettini, T., Yen, C. F., & Cutrell, J. B. (2026) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofag093 · Cited by 6
“Only after clinical studies failed was it discovered that human pulmonary surfactants drastically decreased the activity of daptomycin, explaining the poor clinical outcomes [10].”
Daptomycin for the treatment of major gram-positive infections after cardiac surgery
Kornberger, A., Luchting, B., Kur, F., Weis, M., Weis, F. C., Stock, U. A., & Beiras-Fernández, A. (2016) · Journal of Cardiothoracic Surgery · doi:10.1186/s13019-016-0519-7 · Cited by 6
“Of the remaining patients, those in whom the respiratory tract was designated as the primary focus of infection deserve mention because daptomycin is expressly not recommended for treatment of pulmonary infections [64, 65].”
BackgroundDaptomycin avoids drug resistance mediated by the BceAB transporter in Streptococcus pneumoniae
Faure, A., Manuse, S., Gonin, M., Grangeasse, C., Jault, J., & Orelle, C. (2024) · Microbiology Spectrum · doi:10.1128/spectrum.03638-23 · Cited by 7
“Although daptomycin is strongly active against S. pneumoniae in vitro (22–24), it is inhibited by lung surfactant (25) and hence is not effective for the treatment of pneumonia (26, 27).”
BackgroundTime for a Worldwide Shift from Oral Polio Vaccine to Inactivated Polio Vaccine
Shahzad, A. (2009) · Clinical Infectious Diseases · doi:10.1086/605691 · Cited by 6
Daptomycin eosinophilic pneumonia: an adverse effect to be aware of.
Abelenda-Alonso, G., Rodríguez, M., Martín Torres, J., & Loarte, P. D. V. (2018) · PubMed Central · Cited by 6
Mootz, M. L., Britt, R. S., Mootz, A. A., Lee, G. C., Reveles, K. R., Evoy, K. E., Teng, C., & Frei, C. R. (2019) · Hospital Practice · doi:10.1080/21548331.2019.1676540 · Cited by 6
“It is not appropriate to evaluate the treatment success of daptomycin in treating sepsis secondary to pneumonia, as daptomycin is not effective in respiratory infections due to inactivation by lung surfactant [16].”
BackgroundEffect of Susceptibility Testing Conditions on the In Vitro Antibacterial Activity of ETX0914
GIACOBBE, R. A., Huband, M. D., DeJonge, B. L. M., & Bradford, P. A. (2016) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2016.03.007 · Cited by 6
“Daptomycin requires divalent cations to show good activity (Barry et al., 2001), and its activity is greatly compromised by thepresence of pulmonary surfactant (Silverman et al., 2005),whereas incubation in a CO2 environment has an adverse effect on the activity ofmacrolides (DeVecchi et al., 2008).”
BackgroundDaum, R. S. (2012) · Elsevier eBooks · doi:10.1016/b978-1-4377-2702-9.00117-3 · Cited by 6
Principles of Anti-infective Therapy
Eliopoulos, G. M., & Moellering, R. C. (2015) · Elsevier eBooks · doi:10.1016/b978-1-4557-4801-3.00017-5 · Cited by 10
Ammerlaan, H., & Bonten, M. J. M. (2006) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2006.01627.x · Cited by 9
“Daptomycin did not meet statistical non-inferiority criteria in a clinical trial for severe community-acquired pneumonia; in-vitro studies showed an interaction between daptomycin and lung surfactant, resulting in inhibition of antibacterial activity [55].”
BackgroundMethicillin-resistant Staphylococcus aureus: From the hospital to the community
Paez, A., & Skiest, D. J. (2008) · Current Infectious Disease Reports · doi:10.1007/s11908-008-0005-z · Cited by 6
“However, daptomycin should not be used to treat pneumonia, because pulmonary surfactant inactivates it [ 79 ].”
BackgroundManagement of healthcare-associated methicillin-resistantStaphylococcus aureus
Hsu, L. Y., Wijaya, L., & Tan, B. H. (2005) · Expert Review of Anti-infective Therapy · doi:10.1586/14787210.3.6.893 · Cited by 8
Treatment and recurrence management of staphylococcal infections: community-acquired MRSA
Kale-Pradhan, P. B., & Johnson, L. B. (2008) · Expert Review of Anti-infective Therapy · doi:10.1586/14787210.6.6.909 · Cited by 7
Antibiotics in the Critically Ill
Shorr, A. F. (2012) · CHEST Journal · doi:10.1378/chest.11-3325 · Cited by 6
Yuan, X., Song, X., Zhang, X., Hu, L., Zhou, D., Zhang, J., & Dai, C. (2024) · Virulence · doi:10.1080/21505594.2024.2367659 · Cited by 5
“Additionally, the management of significant infections often necessitates second-line antibiotic therapies, such as tigecycline and daptomycin, which may come with higher costs, reduced effectiveness, and a greater risk of toxicity compared to first-line antibiotic therapies [6,7].”
Fratoni, A. J., Padgett, A. M., Roenfanz, H. F., Duffy, E. M., & Nicolau, D. P. (2024) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkae432 · Cited by 5
Yeni Bir Antibakteriyel Ajan: DAPTOMİSİN
KUTLU, B. G. Y. (2010) · Ankara Üniversitesi Tıp Fakültesi Mecmuası · doi:10.1501/tipfak_0000000767 · Cited by 5
“Kreatinin klirensi 30 ml/dk’nın altında olan hastalarda doz ayarlaması yapılmalı ve ilaç 48 saate bir 4 mg/kg olarak uygulanmalıdır (9, 10, 11)”
A54145 Factor D Is Not Less Susceptible to Inhibition by Lung Surfactant than Daptomycin
Moreira, R., & Taylor, S. D. (2022) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.2c00313 · Cited by 5
Cao, X., Huang, L. J., Tang, M., Liang, Y., Liu, X., Hou, H., & Liang, S. (2024) · Virulence · doi:10.1080/21505594.2024.2339703 · Cited by 5
“The antibacterial effect of DAP against Staphylococci decreased with increasing surfactant concentration when pulmonary surfactant was added, even the antibacterial potency of DAP was lost 16–32 fold when 1% surfactant was added [29].”
de Lima, I. A., Fiuza, L. G., Tovar, J. S. D., Bejar, D. S. L., Tomé, A. J. B., Requena, M. B., Pires, L., Zheng, G., Inada, N. M., Kurachi, C., et al. (2024) · Journal of Photochemistry and Photobiology · doi:10.1016/j.jpap.2024.100252 · Cited by 7
Hagiya, H., Hagioka, S., & Otsuka, F. (2013) · Internal Medicine · doi:10.2169/internalmedicine.52.0023 · Cited by 5
“However, as discussed above, respiratory infection is the exception; DAP-surfactant interactions in the alveolar tissue impair its antibacterial activity (41).”
BackgroundHome Parenteral Nutrition in Patients with Intestinal Failure: Possible Undetected Complications
Santarpia, L., Viceconte, G., Foggia, M., Alfonsi, L., Tosone, G., Camera, L., Pagano, M. C., Simone, G. D., Contaldo, F., & Pasanisi, F. (2019) · Nutrients · doi:10.3390/nu11030581 · Cited by 5
“Unfortunately, it is still unknown if its efficacy in treating septic thromboemboli in lung vessels is as successful as in other extrapulmonary sites [12,13].”
BackgroundAlternative Strategies for Proof-of-Principle Studies of Antibacterial Agents
Dalhoff, A., Weintraub, A., & Nord, C. E. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02473-14 · Cited by 5
“This discrepancy between nonclinical model systems and efficacy in humans is due to the fact that daptomycin inserts itself into human surfactant aggregates in a calcium-dependent manner, so that it is inactivated within the human airway (56).”
Principles Governing Antimicrobial Therapy in the Intensive Care Unit
Godke, J., & Karam, G. H. (2008) · Elsevier eBooks · doi:10.1016/b978-032304841-5.50054-6 · Cited by 5
Koplowicz, Y. B., Schwartz, B. S., & Guglielmo, B. J. (2009) · Clinical Infectious Diseases · doi:10.1086/605690 · Cited by 5
“This case supports laboratory findings that even a small amount of surfactant (1%) results in a 16–32-fold loss of potency of daptomycin [4].”
ResultInvasive Staphylococcus aureus infections in diabetes mellitus
Hakeem, L. M., Laing, R. B. S., Tonna, I., Douglas, J. G., & Mackenzie, A. R. (2013) · The British Journal of Diabetes · doi:10.1177/1474651413500830 · Cited by 6
Potashman, M. H., Formella, D. N., Hamed, K. A., & Mohr, J. (2015) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dku513 · Cited by 5
The Concern for Vancomycin Failure in the Treatment of PediatricStaphylococcus aureusDisease
Thomsen, I. P. (2018) · Clinical Infectious Diseases · doi:10.1093/cid/ciy497 · Cited by 5
“(For cases of pneumonia, however, daptomycin is not recommended for use due to its inactivation by surfactant [14], though its role in hematogenous pulmonary infection is less clear [15].”
BackgroundDaptomycin-Induced Pulmonary Toxicity: A Case Series
Patel, Y., NATARAJAN, S., Ramakrishna, S., & Ochieng, P. (2023) · Cureus · doi:10.7759/cureus.39613 · Cited by 4
“It is avoided in the treatment of bronchoalveolar pneumonia due to its inactivation by alveolar surfactant [5].”
BackgroundTverdek, F. P., Escobar, Z. K., Liu, C., Jain, R., & Lindsay, J. (2023) · Transplant Infectious Disease · doi:10.1111/tid.14129 · Cited by 5
“38 Daptomycin is associated with rhabdomyolysis and elevations in creatinine phosphokinase (CPK)whichshouldbemonitoredweekly.”
BackgroundRasheed, S., Umstätter, F., Mühlberg, E., Beijer, B., Hertlein, T., Klika, K. D., Kleist, C., Werner, J., Domhan, C., Bingel, M., et al. (2025) · Advanced Therapeutics · doi:10.1002/adtp.202400473 · Cited by 4
Ohkoshi, Y., Sato, T., Wada, T., Fukushima, Y., Murabayashi, H., Takakuwa, Y., Nishiyama, K., Honda, H., Shiraishi, T., Kuronuma, K., et al. (2018) · Journal of Infection and Chemotherapy · doi:10.1016/j.jiac.2018.01.012 · Cited by 4
Chan, A., Cross, J. T., He, Y. Q., Lippa, B., & Ryan, D. (2013) · Drug Discovery · doi:10.1002/9781118354483.ch10 · Cited by 4
Improved total synthesis of the antibiotic A54145B
Chow, H. Y., Chen, D., & Li, X. (2020) · Organic & Biomolecular Chemistry · doi:10.1039/d0ob00558d · Cited by 4
Kleijn, L. H. J., Vlieg, H. C., Wood, T. M., Toraño, J. S., Janssen, B. J. C., & Martin, N. I. (2017) · Angewandte Chemie · doi:10.1002/ange.201709240 · Cited by 4
O uso de antimicrobianos na covid-19: uma análise usando a dose diária definida
Ramos, H. G., Ferreira, F. M., & Roriz, T. D. S. (2023) · Health Residencies Journal - HRJ · doi:10.51723/hrj.v4i21.784 · Cited by 4
Clinical pharmacology of antiinfective drugs
Wade, K. C., & Benjamin, D. K. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-79525-8.00049-4 · Cited by 4
Shiraishi, C., Kato, H., Ogura, T., & Iwamoto, T. (2024) · Journal of Infection and Chemotherapy · doi:10.1016/j.jiac.2024.08.016 · Cited by 4
Anti-infective Drug Development for MRSA
Daniel, A. (2013) · Methods in molecular biology · doi:10.1007/978-1-62703-664-1_17 · Cited by 5
Reprogramming Daptomycin and A54145 Biosynthesis to Produce Novel Lipopeptide Antibiotics
Baltz, R. H., Nguyen, K. T., & Alexander, D. C. (2010) · Wiley eBooks · doi:10.1002/9780470627303.ch9 · Cited by 4
Torjani, A., Selbst, D., Hamsher, J., Mujumdar, S., Belkoff, A., & Taboada, L. (2022) · Clinical Medicine Insights Case Reports · doi:10.1177/11795476221078532 · Cited by 4
Soriano, F. G. (2008) · Enfermedades Infecciosas y Microbiología Clínica · doi:10.1157/13123562 · Cited by 4
Genetic Engineering of Acidic Lipopeptide Antibiotics
Baltz, R. H., Nguyen, K. T., & Alexander, D. C. (2014) · ASM Press eBooks · doi:10.1128/9781555816827.ch27 · Cited by 4
Papel de la daptomicina en el tratamiento de las infecciones en el paciente oncohematológico
Salavert, M., & Calabuig, E. (2010) · Medicina Clínica · doi:10.1016/s0025-7753(10)70039-7 · Cited by 4
Garnacho‐Montero, J., Amaya‐Villar, R., Grande, M. L. G., Gómez-Coronado, V. J., Ramos, L. L., Vázquez, A. L., Pellús, A. M., Laderas, J. C. P., Camerino, R. S., Mora, J. P., et al. (2011) · PubMed · Cited by 4
The global epidemiology of MRSA
Tiseo, G., Galfo, V., & Falcone, M. (2026) · JAC-Antimicrobial Resistance · doi:10.1093/jacamr/dlag152 · Cited by 3
“113,114 120 The risk of rhabdomyolysis and creatine phosphokinase elevation, and the rare risk of eosinophilic pneumonia may be more pronounced in special populations, such as elderly patients.”
Metadata
- Authors
- Silverman, J. A., Mortin, L. I., VanPraagh, A. D. G., Li, T., & Alder, J.
- Affiliations
- Cubist Pharmaceuticals (United States) (US)
- Corresponding author
- Silverman, Jared A.
- Venue
- The Journal of Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2005-06-15
- Volume
- 191
- Issue
- 12
- Pages
- 2149-2152
- ISSN
- 0022-1899 (ISSN-L)
- 1537-6613
- OpenAlex
- W2108525727
- Cited by
- 541
- References
- 18
- Citations by year
- 2026: 17 · 2025: 14 · 2024: 25 · 2023: 18 · 2022: 23 · 2021: 23 · 2020: 18 · 2019: 20 · 2018: 24 · 2017: 24 · 2016: 20 · 2015: 24 · 2014: 22 · 2013: 25 · 2012: 28
- FWCI
- 23.82
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Infectious Diseases (publishedVersion)
- PubMed (publishedVersion)
- HighWire Press Open Archive (submittedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Antibiotics Pharmacokinetics and Efficacy
- Health Sciences › Medicine › Epidemiology › Pneumonia and Respiratory Infections
- Life Sciences › Immunology and Microbiology › Microbiology › Antimicrobial Peptides and Activities
- Keywords
- daptomycin, pulmonary surfactant, antibiotic inhibition, lipopeptide antibiotics, Staphylococcus aureus, Streptococcus pneumoniae, community-acquired pneumonia, inhalational anthrax, antibiotic-drug interactions
- MeSH terms
- Animals, Anti-Bacterial Agents, Lung, Microbial Sensitivity Tests, Pneumococcal Infections, Pulmonary Surfactants, Staphylococcal Infections, Daptomycin, Pneumonia, Bacterial, Drug Resistance, Bacterial, Mice, Rats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.